family with sequence similarity 209 member AGenealiases: C20orf106 · dJ1153D9.3
Q-omics provides the consensus-scored FAM209A profile across patient tissues and cancer cell-line models. FAM209A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM209A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM209A protein abundance shows 24,953 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where FAM209A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM209A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM209A survival associations across molecular data types. FAM209A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM209A RNA expression–survival associations across cancer types. High FAM209A expression shows unfavorable associations in KIRC, ACC, LGG and THCA, but favorable associations in HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM209A RNA expression.
This table summarizes FAM209A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM209A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM209A shows lower tumor expression in LUSC and higher tumor expression in KIRC, LIHC, BLCA, STAD and CHOL. The KIRC box plot shows higher FAM209A RNA expression in tumor versus normal tissue (log2 FC = +0.201, t-test p < 0.001).
This table shows molecular features associated with FAM209A in patient tissues and cancer cell lines. In patient samples, FAM209A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM209A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
